Neoadjuvant chemotherapy versus primary surgery in patients with stage III/IV endometrial cancer: A National Cancer Database study. RFS in PORTEC-3 (5-year) and tempus RWD (18-month).
HER2 status was determined by immunohistochemistry (IHC) and dual in situ hybridization (DISH) on four studies of previously classified high-risk EC (PORTEC-3 and Medical Spectrum Twente cohort), ...
Following a successful pilot program on the Canadian Pacific Northern Ontario Service Area and last year’s Total Friction Management™ program rollout in Western Canada, Portec Rail Products, Inc. is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results